We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
Consensus vs. actual, and revenue trend
| 분기 | 발표일 | 시각 | EPS 예상 | EPS 실제 | 서프라이즈 | 매출 예상 | 매출 실제 | 상태 |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 04. | 장 마감 후 (AMC) | $-0.07 | — | — | $76.6M | — | 예정 |
| FY2026 Q1 | 2025. 03. 31. | 시각 미정 | — | $-0.21 | — | — | $65M | 보고됨 |
| FY2025 Q3 | 2024. 09. 30. | 시각 미정 | — | $-0.17 | — | — | $263.2M |
Consensus PT $3.19 · 4 analysts
| 날짜 | 리서치펌 | 애널리스트 | 액션 | 의견 변화 | 목표가 | 리포트 |
|---|---|---|---|---|---|---|
| 2026. 05. 05. | Needham | — | 투자의견 하향 | Buy → Hold | — | Needham: Buy → Hold |
| 2026. 05. 02. | HC Wainwright & Co. | — | 투자의견 하향 | Buy → Neutral | — | HC Wainwright & Co.: Buy → Neutral |
동일 리서치펌의 과거 의견 변화, 동일 섹터 내 다른 종목 액션과 비교 가능
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
미국 증권사 투자의견/등급 변경.
| FY2025 Q2 | 2024. 06. 30. | 시각 미정 | — | $-0.01 | — | — | $211.57M | 보고됨 |
Automated summary from public sources · not investment advice
공시·실적·기관 변화를 한국어 한 단락으로 요약. 원문 출처와 함께 제공됩니다.
Ranked by position value
표시할 보유 데이터가 없습니다.
신규 편입·전량 매도·비중 변화까지 모두 확인할 수 있습니다.
Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia cardiovascular disease who require additional lowering of LDL-C. Its products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. It has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was formerly known as HDL Therapeutics, Inc. and changed its name to Esperion Therapeutics, Inc. in May 2008. The company was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Stored first · Google News · Yahoo Finance (English)
Esperion (NASDAQ: ESPR) director receives 79,873-share stock award grant - Stock Titan
Esperion (NASDAQ: ESPR) director receives 79,873-share stock award grant Stock Titan
Esperion Therapeutics (ESPR) director receives 79,873-share stock award - Stock Titan
Esperion Therapeutics (ESPR) director receives 79,873-share stock award Stock Titan
Esperion (NASDAQ: ESPR) director receives 79,873-share stock grant - Stock Titan
Esperion (NASDAQ: ESPR) director receives 79,873-share stock grant Stock Titan
Director at Esperion (NASDAQ: ESPR) receives 79,873-share stock grant - Stock Titan
Director at Esperion (NASDAQ: ESPR) receives 79,873-share stock grant Stock Titan
Director at Esperion Therapeutics (ESPR) receives 79,873-share equity award - Stock Titan
Director at Esperion Therapeutics (ESPR) receives 79,873-share equity award Stock Titan
Esperion (NASDAQ: ESPR) investors approve 7M-share plan boost and board slate - Stock Titan
Esperion (NASDAQ: ESPR) investors approve 7M-share plan boost and board slate Stock Titan